Major Depressive Disorder

Adults with Major Depressive Disorder (MDD), with or without Anxious Distress.

This Phase 2, randomized, double-blind, placebo-controlled study is evaluating an investigational oral antidepressant as an add-on treatment for adults with major depressive disorder (MDD) who continue to experience moderate to severe symptoms despite taking standard antidepressant therapy. Major Depressive Disorder is a chronic and debilitating mental health condition characterized by persistent sadness, loss of interest, and impaired functioning. Although multiple antidepressants are FDA-approved, many patients do not respond adequately. This study seeks to determine whether this add-on medication can improve depressive symptoms compared with placebo. The trial will assess both the efficacy and safety of the study medication, with the goal of better understanding its potential as a personalized, well-tolerated treatment option for individuals with depression.